Novo Nordisk A/S (NVO)
| Market Cap | 564.65B |
| Revenue (ttm) | 35.35B |
| Net Income (ttm) | 12.92B |
| Shares Out | 4.25B |
| EPS (ttm) | 2.89 |
| PE Ratio | 46.14 |
| Forward PE | 39.53 |
| Dividend | $0.98 (0.73%) |
| Ex-Dividend Date | Mar 22, 2024 |
| Volume | 2,805,291 |
| Open | 132.18 |
| Previous Close | 132.41 |
| Day's Range | 131.30 - 133.00 |
| 52-Week Range | 75.56 - 138.28 |
| Beta | 0.20 |
| Analysts | Strong Buy |
| Price Target | 133.00 (+0.06%) |
| Earnings Date | May 2, 2024 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $133.0, which is an increase of 0.06% from the latest price.
News
Novo Nordisk owner buys majority stake in Austrian life science tools company
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , said on Wednesday it would buy a controlling stake of about 60% in Single Use Support, an Austria-based life scien...
No shortage of Wegovy weight-loss drug in Denmark, Novo Nordisk says
Novo Nordisk does not expect a shortage of its Wegovy weight-loss drug in Denmark despite an earlier warning by the Danish Medicines Agency of strained supply of two separate doses in the coming weeks...
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says
A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind's new AI model can predict the structure of molecules.
People on Novo Nordisk's Wegovy maintain weight loss for up to four years, study says
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to cover the costly drug.
Cramer's Stop Trading: Novo Nordisk
CNBC's Jim Cramer explains why he is keeping an eye on shares of Novo Nordisk.
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday.
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 peo...
Denmark faces Wegovy shortage due to rising demand, medicines agency says
The Danish medicines agency on Monday warned of a supply shortage for two separate doses of Novo Nordisk's hugely popular weight loss drug Wegovy due to increasing demand.
Bernie Sanders Urges Ozempic Maker Novo Nordisk To Be Fair Over ‘Outrageously Expensive' U.S. Drug Prices
Bernie Sanders has urged Denmark to rein in its most valuable company, Novo Nordisk, and force it to slash prices on popular weight loss and diabetes treatments Ozempic and Wegovy, taking his fight to...
Metaphore Biotechnologies to partner with Novo Nordisk on obesity therapies
Metaphore Biotechnologies said on Thursday it would collaborate with Novo Nordisk to develop up to two therapies for obesity management.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons i...
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart monitoring tech was approved for use in clinical studies.
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons ...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S' overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new s...
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme
Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The...
Gates Foundation joins Novo Nordisk, Wellcome on $300M global health effort
The Bill & Melinda Gates Foundation is committing $100 million to a new joint partnership that will support innovation and research that address global health challenges.
Gates, Novo Nordisk And Wellcome Commit $300 Million To Climate Change, Infectious Diseases And Nutrition
The Bill & Melinda Gates Foundation, Wellcome Trust and Novo Nordisk Foundation joined forces on Monday to tackle some of the world's most pressing health problems, an endeavor that pulls together thr...
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.
Wegovy maker Novo Nordisk down 4%, heads for worst day since October
Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
US FTC seeks more information on Novo Nordisk parent-Catalent deal
The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent.
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReS...
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its e...
Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price cut
Novo Nordisk said it will cut prices of Wegovy amid rising sales and competition. Sales of the blockbuster drug more than doubled in the first quarter year-on-year.
Novo Nordisk falls after strong Q1 results, Mizuho's Jared Holz talks what's next for the company
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk pulling back despite strong quarter.